Cover Image
市場調查報告書

多發性硬化症治療藥:全球市場與研究開發 (R&D)的未來展望:2016∼2026年

Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026

出版商 Visiongain Ltd 商品編碼 226946
出版日期 內容資訊 英文 151 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
多發性硬化症治療藥:全球市場與研究開發 (R&D)的未來展望:2016∼2026年 Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026
出版日期: 2016年06月03日 內容資訊: 英文 151 Pages
簡介

本報告提供多發性硬化症 (MS) 治療藥的市場相關分析,提供您疾病概要和主要的治療方法,目前主要治療藥簡介和銷售額預測 (過去5年·今後11年份),現在臨床實驗中的主要開發平台候補藥 (臨床實驗的進展,銷售額預測等),世界市場趨勢預測和主要的促進·阻礙因素,各市場區隔·各地區·主要國家詳細趨勢,今後的市場成長·產品開發的方向性等調查評估。

第1章 分析概要

第2章 多發性硬化症的概要

  • 多發性硬化症是什麼?
    • 主要統計:全球250萬人罹患
  • 多發性硬化症的病理
    • 症狀
  • 多發性硬化症的診斷
  • 多發性硬化症的評估
  • 多發性硬化症的各種種類
    • 復發型多發性硬化症 (RRMS)
    • 次發漸進型多發性硬化症
    • 漸進復發型多發性硬化症
    • 首發漸進型多發性硬化症
    • 其他發病形態
  • 可推估的多發性硬化症原因因素
    • 遺傳性要素
    • 感染
    • 環境要素,及支持率較低的學說
  • 患者數與地區分佈
  • 多發性硬化症的各種治療手段

第3章 多發性硬化症的主要的治療藥

  • Copaxone (glatiramer acetate):Teva Pharmaceutical Industries
  • Tecfidera (富馬酸二甲酯):Biogen
  • Avonex (干擾素β-1a):Biogen
  • Gilenya (Fingolimod) :Novartis
  • Rebif (干擾素β-1a):Merck KGaA
  • Tysabri (natalizumab):Biogen
  • Betaseron / Betaferon (干擾素β-1a):Bayer
  • Aubagio (teriflunomide):Sanofi
  • Plegridy (PEG干擾素β-1a):Biogen
  • Lemtrada (alemtuzumab):Sanofi

第4章 多發性硬化症的治療藥開發平台 (今後11年份)

  • Ocrelizumab (Ocrevus / RG1594):Roche
  • Ozanimod:Celgene
  • Zinbryta (dashirizumabu的高收穫率流程):Biogen·AbbVie
  • ofatsumumabu:Novartis
  • poneshimodo:Actelion
  • laquinimod:Teva·Active Biotech
  • MED1003:MedDay
  • mashichinibu:AB Science - 到達第三階段了,但有效性未通過核可
  • shiponimodo (BAF312):Novartis - Gilenya的競爭對手

第5章 全球多發性硬化症治療藥市場

  • 世界市場趨勢預測 (今後11年份)
  • 市場成長的主要的推動因素
    • 現有產品的銷售額擴大:暢銷藥物的銷售額在專利到期前達到頂點
    • 今後10年多數新產品上市
    • 產品價格上升及維持高水準
    • 多發性硬化症的患病人數·發病量的增加
    • 未滿足需求與策略性聯盟
  • 市場成長的主要阻礙因素
    • 許多藥物專利即將到期,將面臨與學名藥·生技仿製藥的競爭
    • 伴隨醫療費削減的價格壓力
    • 市場參與企業多

第6章 治療藥的主要市場區隔:市場收益額預測

  • 多發性硬化症治療藥市場:主要各市場區隔的預測 (今後11年份)
  • 主要治療藥的市場佔有率:最新值·預測值
  • 單株抗體
  • S1PR修飾藥
  • 干擾素
  • 其他免疫調節藥物
  • 「其他」的領域

第7章 各國多發性硬化症治療藥的市場:市場收益額預測

  • 多發性硬化症的發病數量·患病人數
  • 主要國家的市場規模的預測值 (今後11年份)
    • 各國比較分析 (最新值·預測值)
  • 美國市場
    • 美國市場規模極大的理由
    • 現在進行中的變化
    • 市場規模預測 (今後11年份)
  • 歐洲主要5個國家的市場
    • 地區整體共同點:推動市場要素
    • 德國市場
      • 市場規模預測 (今後11年份)
    • 法國市場
    • 英國市場
    • 義大利市場
    • 西班牙市場
  • 加拿大市場
  • 日本市場
  • 中國市場
  • 印度市場

第8章 分析結果

  • 今後的市場成長率的變化
  • 治療藥的市場結構的變化
  • 各國市場的成長預測
  • 結論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0121

Title:
MULTIPLE SCLEROSIS DRUGS MARKET AND R&D OUTLOOK 2016-2026
Revenue Forecasts for Leading Submarkets including Immunomodulators, Interferons, Monoclonal Antibodies and S1PR Modulators, and also Drugs Including Copaxone, Tecfidera, Avonex, Gilenya and Rebif.

MS Drugs - Discover R&D Trends and Markets with Highest Revenue Potentials

Where is the multiple sclerosis drugs market heading? Visiongain's new study predicts that pharma industry's revenues from 2016. There you find potentials for sales growth, also exploring trends, technologies, patients' needs and opportunities.

Our report gives you revenue forecasts to 2026 at overall world market, submarket, product and national level. Avoid falling behind in data. Instead see what is happening for those central nervous system (CNS) drugs, hearing how you can gain in knowledge and benefit your influence.

Please read on to explore those therapies and discover what revenue their future market could generate.

Forecasts to 2026 and other analysis show you commercial prospects

Besides revenue forecasting to 2026, our new study shows you historical and epidemiological data, growth rates and market shares. See progress in products and clinical trials, exploring what the future holds. And you get 81 tables and 48 charts.

With our study you assess trends, demands and sales potentials for MS-treating medicines. You see, from 2016, where needs and money exist. Discover the most lucrative market segments and products, including conventional drugs and biologics.

The following sections explain how you benefit from our new investigation.

Forecasts from 2016 for the world MS medicines market and submarkets

What are the secrets of that industry's progress? See expected trends there. Along with prediction of the overall world market for treating multiple sclerosis, our report shows you revenue forecasting of five therapeutic submarkets to 2026 at world level:

  • Monoclonal antibodies (mAbs)
  • S1PR modulators
  • Interferons
  • Other immunomodulators
  • Other agents.

Our analyses and discussions show you commercial potentials for MS-treating medicines, present and future. Discover those opportunities for improved treatment.

With our study you get the forecasting leaders need, benefiting your authority. Our study's purpose is to help your research, analyses and decisions.

There, in our work, you also find revenue predictions for leading products.

Predictions of leading products' sales - what is possible for those CNS drugs?

How will individual multiple sclerosis medicines perform to 2026 at world level? Our new report shows revenue forecasts to 2026 for 10 leading marketed drugs and three promising candidates in the R&D pipeline:

  • Copaxone (glatiramer acetate) by Teva Pharmaceutical Industries
  • Tecfidera (dimethyl fumarate) by Biogen
  • Avonex (interferon beta-1a) by Biogen
  • Gilenya (fingolimod) by Novartis
  • Rebif (interferon beta-1a) by Merck KGaA
  • Tysabri (natalizumab) by Biogen
  • Betaseron/Betaferon (interferon beta-1b) by Bayer
  • Aubagio (teriflunomide) by Sanofi
  • Plegridy (peginterferon beta-1a) by Biogen
  • Lemtrada (alemtuzumab) by Sanofi
  • Ocrelizumab (Ocrevus / RG1594) by Roche
  • Ozanimod by Celgene
  • Zinbryta (daclizumab high-yield process) by Biogen and AbbVie.

In our study you see how high sales can go, finding products and years with highest predicted revenues. You also examine competition. That way you investigate what is happening, exploring challenges, trends, competitors and opportunities.

Discover what the future holds for treating multiple sclerosis. Our work also shows you geographical predictions by leading country.

National and regional markets - what outlooks for demand and sales?

In developed and developing countries, opportunities for MS drug developers and producers will occur from 2016, leading to revenue gains. Find the most promising markets.

Our investigation shows revenue forecasts to 2026 for 10 leading national markets for multiple sclerosis drugs:

  • US
  • Japan
  • Canada
  • Germany, France, UK, Italy and Spain
  • India and China.

There you explore progress and outlooks. You assess that those medicines' future - hear about developments, also finding their meaning and sales potentials.

That way you find opportunity and assess challenges. Our work explains what the future holds, exploring issues affecting those pharmaceutical companies.

Forces affecting MS drug producers and the healthcare needs they serve

Our report shows you activities, developments and events affecting that industry and market from 2016, including these influences:

  • Demographics and geographical distribution
  • Prevalence and incidence of multiple sclerosis
  • Disease modifying treatments
  • Immunomodulators, monoclonal antibodies, S1PR modulation and other drug classes on the market and in development
  • Challenges from generics and biosimilars
  • Patent protection and regulatory affairs.

With our survey you explore political, economic, social and technological questions, assessing outlooks for business. You examine forces stimulating and restraining that pharmaceutical market.

You also assess the most promising aspects of that industry's research and development. Discover what that pharma sector's present and future hold.

Leading companies and overall 2020 market value - how high can sales go?

What is possible there? Our analysis predicts the overall world market for MS drugs will reach $23.2 billion in 2020. It will show revenue expansion from 2016 to 2026, giving companies high commercial potentials.

In particular our study explores activities, capabilities and results of these firms:

  • Biogen
  • Teva Pharmaceutical Industries
  • Novartis
  • Merck KGaA
  • Bayer
  • Sanofi
  • Roche
  • Celgene.

In our work you assess companies' results, strengths and outlooks. So discover where that industry heads, helping you stay ahead in knowledge and succeed.

5 main ways Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026 helps - gain data found nowhere else

Our new investigation helps you in these five main ways, benefiting your research, plans, decisions and presentations:

  • Revenues to 2026 for MS drugs at overall world level - explore commercial potentials for companies, their drug development and products
  • Prospects of 5 therapeutic submarkets and 13 drugs to 2026 - discover the revenue generating potentials of existing and expected MS medicines
  • Forecasts to 2026 for 10 national markets in North America, Europe and Asia - investigate developed and developing countries' revenue potentials
  • Outlooks for established and rising MS drug companies - assess portfolios, results and prospects of developers, producers and marketers
  • Analysis of what stimulates and restrains that large, expanding pharma market - explore that segment's trends, helping you compete and succeed.

That report, by our in-house analysts in the UK, could benefit your reputation for knowledge, helping you succeed. Gain analysis leading companies depend on.

Data found nowhere else, helping your research, assessments and planning

Our new report gives you independent analysis. You receive business intelligence found only in our work. With that study you are less likely to fall behind in data or miss opportunity. Instead discover what the future holds for your business.

That way discover where prospects and money exist. Our investigation's purpose is to benefit your research, analysis and decisions, also saving you time and effort.

Prospects for drugs treating multiple sclerosis - explore that market's future

Our new study is for everyone investigating the potential of existing and new CNS drugs. There, for MS, you find revenue forecasting from 2016, seeing trends, progress and discussions. Avoid missing out - please get our report here now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Multiple Sclerosis Drugs Market Overview
  • 1.2. Why You Should Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Main Questions Answered by this Report
  • 1.5. Who is this Report for?
  • 1.6. Research and Analysis Methods
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Some Associated Reports
  • 1.9. About Visiongain

2. Introduction to Multiple Sclerosis

  • 2.1. What is Multiple Sclerosis?
    • 2.1.1. Key Statistics: 2.5 Million Sufferers in the World
  • 2.2. The Pathology of MS
    • 2.2.1. Symptoms
  • 2.3. Diagnosis of MS
    • 2.3.1. Tests for MS Include These Technologies
  • 2.4. Measuring MS
  • 2.5. The Different Types of MS
    • 2.5.1. Relapsing-Remitting MS (RRMS)
    • 2.5.2. Secondary Progressive MS
    • 2.5.3. Progressive Relapsing MS
    • 2.5.4. Primary Progressive MS
    • 2.5.5. Other Presentations of the Disease
  • 2.6. Possible Causational Factors for MS
    • 2.6.1. Genetic Factors
    • 2.6.2. Infection
    • 2.6.3. Environmental Factors and Less Well-Supported Theories
  • 2.7. Demographics and Geographical Distribution
  • 2.8. Different Treatments for MS

3. Leading Multiple Sclerosis Drugs

  • 3.1. Copaxone (glatiramer acetate) by Teva Pharmaceutical Industries
    • 3.1.1. First Non-Interferon Immunomodulator
    • 3.1.2. Teva and the Approval of Generic Competition
    • 3.1.3. The First Generic is Approved - Sandoz's Glatopa
    • 3.1.4. Industry Surprised by Copaxone's Solid Sales, Despite Generic Competition: 40mg Dose is Key
    • 3.1.5. Patents on Copaxone 40mg Being Contested - Although Teva Receives Good News in Europe
    • 3.1.6. Copaxone Revenues 2011-2015
    • 3.1.7. Copaxone Revenue Forecast 2016-2026
  • 3.2. Tecfidera (dimethyl fumarate) by Biogen
    • 3.2.1. Rapidly Grown Since 2013 to Become the Leading Oral MS Therapy
    • 3.2.2. Tecfidera Revenues 2013-2015
    • 3.2.3. Tecfidera Revenue Forecast 2016-2026
  • 3.3. Avonex (interferon beta-1a) by Biogen
    • 3.3.1. The Leading Interferon Therapy
    • 3.3.2. Avonex Revenues 2011-2015
    • 3.3.3. Patent Extension to 2026
    • 3.3.4. Avonex Revenue Forecast 2016-2026
  • 3.4. Gilenya (fingolimod) by Novartis
    • 3.4.1. The First Oral Disease-Modifying Drug for MS
    • 3.4.2. US Patent Trial and Appeal Board Sides Against Novartis
    • 3.4.3. Gilenya Revenues 2011-2015
    • 3.4.4. Gilenya Revenue Forecast 2016-2026
  • 3.5. Rebif (interferon beta-1a) by Merck KGaA
    • 3.5.1. Merck Attempting to Differentiate Rebif from Other Interferon Therapies
    • 3.5.2. Rebif Revenues 2011-2015
    • 3.5.3. Rebif Revenue Forecast 2016-2026
  • 3.6. Tysabri (natalizumab) by Biogen
    • 3.6.1. High Efficacy Offsets the Risks
    • 3.6.2. Tysabri Revenues 2011-2015
    • 3.6.3. Tysabri Revenue Forecast 2016-2026
  • 3.7. Betaseron / Betaferon (interferon beta-1b) by Bayer
    • 3.7.1. First Disease Modifying Drug for MS
    • 3.7.2. Betaseron Revenues 2011-2015
    • 3.7.3. Betaseron Revenue Forecast 2016-2026
  • 3.8. Aubagio (teriflunomide) by Sanofi
    • 3.8.1. More than 48,000 Patients Treated
    • 3.8.2. Aubagio Revenues 2014-Q1 2016
    • 3.8.3. Aubagio Revenue Forecast 2016-2026
  • 3.9. Plegridy (peginterferon beta-1a) by Biogen
    • 3.9.1. 36% Reduction in ARR compared to Placebo
    • 3.9.2. Plegridy Revenues 2014-2015
    • 3.9.3. Plegridy Revenue Forecast 2016-2026
  • 3.10. Lemtrada (alemtuzumab) by Sanofi
    • 3.10.1. Very Effective, but with Side Effects
    • 3.10.2. Lemtrada Past Revenues and Revenue Forecast 2016-2026

4. Multiple Sclerosis Drugs Pipeline 2016-2026

  • 4.1. Ocrelizumab (Ocrevus / RG1594) by Roche
    • 4.1.1. Humanised mAb Targeting CD20
    • 4.1.2. First Drug to Receive Breakthrough Therapy Designation for MS
    • 4.1.3. Exciting Latest Results from Two Phase 3 Trials
    • 4.1.4. Ongoing Clinical Trials
    • 4.1.5. Ocrelizumab Revenue Forecast 2016-2026
  • 4.2. Ozanimod by Celgene
    • 4.2.1. S1PR Modulator
    • 4.2.2. Promising Results from Phase 2 RADIANCE Study
    • 4.2.3. Ongoing Clinical Trials
    • 4.2.4. Ozanimod in MS Revenue Forecast 2018-2026
  • 4.3. Zinbryta (daclizumab high-yield process) by Biogen and AbbVie
    • 4.3.1. Humanised mAb Being Jointly Developed by two Giants
    • 4.3.2. Positive Opinion on Marketing Authorisation from the CHMP
    • 4.3.3. Zinbryta Revenue Forecast 2016-2026
  • 4.4. Ofatumumab by Novartis
    • 4.4.1. Novartis Acquires Full Remaining Rights in $1bn Agreement
    • 4.4.2. Advantages and Disadvantages over Ocrelizumab
  • 4.5. Ponesimod by Actelion
    • 4.5.1. S1PR Modulator
    • 4.5.2. Positive Earlier Results
  • 4.6. Laquinimod by Teva and Active Biotech
    • 4.6.1. Troubled Oral Immunomodulator
    • 4.6.2. Turned Down for European Licence
  • 4.7. MED1003 by MedDay
    • 4.7.1. Unique Method of Action
    • 4.7.2. Results from MS-SPI and MS-ON
  • 4.8. Masitinib by AB Science: Phase 3 and has Completed a Futility Analysis
  • 4.9. Siponimod (BAF312) by Novartis: Competitor for Gilenya

5. Global Multiple Sclerosis Drugs Market 2016-2026

  • 5.1. Global Multiple Sclerosis Drugs Market Forecast 2016-2026
  • 5.2. What Factors Will Drive Growth in the Global MS Drugs Market?
    • 5.2.1. Growth of Existing Products, Reaching Peak Blockbuster Revenues before Patent Expiry
    • 5.2.2. Exciting New Products Due to be Launched Within the Next Ten Years
    • 5.2.3. Premium Prices, Accompanied by Price Increases
    • 5.2.4. Prevalence and Incidence of Multiple Sclerosis is Increasing
    • 5.2.5. Unmet Needs and Strategic Partnering
  • 5.3. What Factors will Restrain Growth in the Global MS Drugs Market?
    • 5.3.1. Multiple Patent Expiries on Leading Drugs will Lead to Generic and Biosimilar Competition
    • 5.3.2. Declining Healthcare Budgets Could Lead to Cost Pressures
    • 5.3.3. Crowded Marketplace

6. Leading Therapeutic Segments: Revenue Prospects, 2016-2026

  • 6.1. The Main Therapeutic Segments within the MS Drugs Market, Forecast 2016-2026
  • 6.2. Therapeutic Composition of the Market in 2015, 2020 and 2026
  • 6.3. Monoclonal Antibodies Segment Forecast 2016-2026
  • 6.4. S1PR Modulator Segment Forecast 2016-2026
  • 6.5. Interferons Segment Forecast 2016-2026
  • 6.6. Other Immunomodulators Segment Forecast 2016-2026
  • 6.7. ‘Others' Segment Forecast 2016-2026

7. National Markets for MS Drugs: Revenue Prospects, 2016-2026

  • 7.1. Multiple Sclerosis Cases and Prevalence Values
  • 7.2. Leading Regional Markets Forecast 2016-2026
    • 7.2.1. Regional Composition of the Market in 2015, 2020 and 2026
  • 7.3. US MS Drugs Market
    • 7.3.1. Reasons why the US Market Dominates the MS Drugs Market to Such an Extent
    • 7.3.2. Undergoing Some Changes
    • 7.3.3. US MS Drugs Market Forecast 2016-2026
  • 7.4. EU5. MS Drugs Market 2016-2026
    • 7.4.1. Common Characteristics of all the EU5 Nations in Regards to MS Drugs and Drivers of Growth
    • 7.4.2. German MS Drugs Market: Leading EU Market
      • 7.4.2.1. German MS Drugs Market Forecast 2016-2026
    • 7.4.3. French MS Drugs Market: Strong Healthcare System
      • 7.4.3.1. French MS Drugs Market Forecast 2016-2026
    • 7.4.4. UK MS Drugs Market
      • 7.4.4.1. UK MS Drugs Market Forecast 2016-2026
    • 7.4.5. Italian MS Drugs Market
      • 7.4.5.1. Italian MS Drugs Market Forecast 2016-2026
    • 7.4.6. Spanish MS Drugs Market
      • 7.4.6.1. Spanish MS Drugs Market Forecast 2016-2026
  • 7.5. Canadian MS Drugs Market: Country has Highest Rate of MS in the World
    • 7.5.1. Canadian MS Drugs Market Forecast 2016-2026
  • 7.6. Japanese MS Drugs Market Forecast 2016-2026
  • 7.7. Chinese MS Drugs Market Forecast 2016-2026
  • 7.8. Indian MS Drugs Market Forecast 2016-2026

8. Conclusions from Our Research and Analysis

  • 8.1. How will Revenues Change over the Forecast Period?
  • 8.2. How will the Therapeutic Composition of the Market Change?
  • 8.3. How will National Markets Develop from 2016 to 2026?
  • 8.4. Concluding Remarks

List of Tables

  • Table 2.1: The Kurtzke Expanded Disability Scales (EDSS)
  • Table 3.1: Total Copaxone Revenues 2011-2015, Revenues ($m), AGR (%), CAGR (%)
  • Table 3.2: Copaxone Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
  • Table 3.3: Copaxone Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 3.4: Total Tecfidera Revenues 2013-2015, Revenues ($m), AGR (%), CAGR (%)
  • Table 3.5: Tecfidera Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
  • Table 3.6: Tecfidera Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 3.7: Total Avonex Revenues 2011-2015, Revenues ($m), AGR (%), CAGR (%)
  • Table 3.8: Avonex Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
  • Table 3.9: Avonex Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 3.10: Total Gilenya Revenues 2011-2015, Revenues ($m), AGR (%), CAGR (%)
  • Table 3.11: Gilenya Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
  • Table 3.12: Gilenya Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 3.13: Total Rebif Revenues 2011-2015, Revenues ($m), AGR (%), CAGR (%)
  • Table 3.14: Rebif Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
  • Table 3.15: Rebif Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 3.16: Total Tysabri Revenues 2011-2015, Revenues ($m), AGR (%), CAGR (%)
  • Table 3.17: Tysabri Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
  • Table 3.18: Tysabri Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 3.19: Total Betaseron Revenues 2011-2015, Revenues ($m), AGR (%), CAGR (%)
  • Table 3.20: Betaseron Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
  • Table 3.21: Betaseron Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 3.22: Total Aubagio Revenues 2014-2015, Revenues ($m), AGR (%)
  • Table 3.23: Aubagio Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
  • Table 3.24: Aubagio Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 3.25: Total Plegridy Revenues 2014-2015, Revenues ($m), AGR (%)
  • Table 3.26: Plegridy Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
  • Table 3.27: Plegridy Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 3.28: Total Lemtrada Revenues 2013-2015, Revenues ($m), AGR (%), CAGR (%)
  • Table 3.29: Lemtrada Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
  • Table 3.30: Lemtrada Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 4.1: Ocrelizumab: Selected Ongoing Clinical Trials, 2016
  • Table 4.2: Ocrelizumab Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2020
  • Table 4.3: Ocrelizumab Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 4.4: Ozanimod: Selected Ongoing Clinical Trials, 2016
  • Table 4.5: Ozanimod Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2018-2020
  • Table 4.6: Ozanimod Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 4.7: Zinbryta Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2020
  • Table 4.8: Zinbryta Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 4.9: Siponimod: Ongoing MS Clinical Trials, 2016
  • Table 5.1: Total MS Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 5.2: Total MS Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 5.3: Selected MS Drugs Achieving Peak Revenues During Forecast Period: Revenue ($m)
  • Table 6.1: Therapeutic Segments within the MS Drugs Market: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 6.2: Therapeutic Segments within the MS Drugs Market: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.3: Monoclonal Antibodies Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 6.4: Monoclonal Antibodies Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.5: S1PR Modulator Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 6.6: S1PR Modulator Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.7: Interferons Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 6.8: Interferons Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.9: Other Immunomodulators Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 6.10: Other Immunomodulators Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.11: ‘Others' Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 6.12: ‘Others' Segment of the MS Drugs Market, Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 7.1: Total Number of People with MS in the US, EU5, Canada, Japan, China and India, 2013
  • Table 7.2: Prevalence of MS within the Nations Forecasted in this Report: Population Size, Number of People with MS, Prevalence (%), 2013
  • Table 7.3: Regional Forecasts for the Global MS Drugs Market (US, EU5, Canada and Japan): Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 7.4: Regional Forecasts for the Global MS Drugs Market (China, India, ROW and Total Global Market): Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 7.5: Regional Forecasts for the Global MS Drugs Market (US, EU5, Canada and Japan): Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 7.6: Regional Forecasts for the Global MS Drugs Market (China, India, ROW and Total Global Market): Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 7.7: US MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 7.8: US MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 7.9: German MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 7.10: German MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 7.11: French MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 7.12: French MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 7.13: UK MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 7.14: UK MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 7.15: Italian MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 7.16: Italian MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 7.17: Spanish MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 7.18: Spanish MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 7.19: Canadian MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 7.20: Canadian MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 7.21: Japanese MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 7.22: Japanese MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 7.23: Chinese MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 7.24: Chinese MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 7.25: Indian MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 7.26: Indian MS Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026

List of Figures

  • Figure 3.1: Total Copaxone Revenues 2011-2015, Revenues ($m)
  • Figure 3.2: Copaxone Revenue Forecast: Revenue ($m), 2015-2026
  • Figure 3.3: Total Tecfidera Revenues 2013-2015, Revenues ($m)
  • Figure 3.4: Tecfidera Revenue Forecast: Revenue ($m), 2015-2026
  • Figure 3.5: Total Avonex Revenues 2011-2015, Revenues ($m),
  • Figure 3.6: Avonex Revenue Forecast: Revenue ($m), 2015-2026
  • Figure 3.7: Total Gilenya Revenues 2011-2015, Revenues ($m),
  • Figure 3.8: Gilenya Revenue Forecast: Revenue ($m), 2015-2026
  • Figure 3.9: Total Rebif Revenues 2011-2015, Revenues ($m)
  • Figure 3.10: Rebif Revenue Forecast: Revenue ($m), 2015-2026
  • Figure 3.11: Total Tysabri Revenues 2011-2015, Revenues ($m)
  • Figure 3.12: Tysabri Revenue Forecast: Revenue ($m), 2015-2026
  • Figure 3.13: Total Betaseron Revenues 2011-2015, Revenues ($m),
  • Figure 3.14: Betaseron Revenue Forecast: Revenue ($m), 2015-2026
  • Figure 3.15: Aubagio Revenue Forecast: Revenue ($m), 2015-2026
  • Figure 3.16: Plegridy Revenue Forecast: Revenue ($m), 2015-2026
  • Figure 3.17: Lemtrada Revenue Forecast: Revenue ($m), 2015-2026
  • Figure 4.1: Ocrelizumab Revenue Forecast: Revenue ($m), 2016-2026
  • Figure 4.2: Ozanimod Revenue Forecast: Revenue ($m), 2018-2026
  • Figure 4.3: Zinbryta Revenue Forecast: Revenue ($m), 2016-2026
  • Figure 5.1: Total MS Drugs Market Forecast: Revenue ($bn), 2015-2026
  • Figure 5.2: Total MS Drugs Market Forecast Broken Down by Therapeutic Segment (Line Graph): Revenue ($m), 2015-2026
  • Figure 6.1: Therapeutic Composition of the MS Drugs Market: Market Share (%), 2015
  • Figure 6.2: Therapeutic Composition of the MS Drugs Market: Market Share (%), 2020
  • Figure 6.3: Therapeutic Composition of the MS Drugs Market: Market Share (%), 2026
  • Figure 6.4: Monoclonal Antibodies Segment of the MS Drugs Market, Forecast: Revenues ($m), 2015-2026
  • Figure 6.5: S1PR Modulator Segment of the MS Drugs Market, Forecast: Revenues ($m), 2015-2026
  • Figure 6.6: Interferons Segment of the MS Drugs Market, Forecast: Revenues ($m), 2015-2026
  • Figure 6.7: Other Immunomodulators Segment of the MS Drugs Market, Forecast: Revenues ($m), 2015-2026
  • Figure 6.8: ‘Others' Segment of the MS Drugs Market, Forecast: Revenues ($m), 2015-2026
  • Figure 7.1: Global MS Drugs Market by Region: Revenue ($m), 2015-2026
  • Figure 7.2: Regional Composition of the Global MS Drugs Market (Pie Chart): Revenues ($m), 2015
  • Figure 7.3: Regional Composition of the Global MS Drugs Market (Pie Chart): Revenues ($m), 2020
  • Figure 7.4: Regional Composition of the Global MS Drugs Market (Pie Chart): Revenues ($m), 2026
  • Figure 7.5: US MS Drugs Market Forecast: Revenues ($m), 2015-2026
  • Figure 7.6: German MS Drugs Market Forecast: Revenues ($m), 2015-2026
  • Figure 7.7: French MS Drugs Market Forecast: Revenues ($m), 2015-2026
  • Figure 7.8: UK MS Drugs Market Forecast: Revenues ($m), 2015-2026
  • Figure 7.9: Italian MS Drugs Market Forecast: Revenues ($m), 2015-2026
  • Figure 7.10: Spanish MS Drugs Market Forecast: Revenues ($m), 2015-2026
  • Figure 7.11: Canadian MS Drugs Market Forecast: Revenues ($m), 2015-2026
  • Figure 7.12: Japanese MS Drugs Market Forecast: Revenues ($m), 2015-2026
  • Figure 7.13: Chinese MS Drugs Market Forecast: Revenues ($m), 2015-2026
  • Figure 7.14: Indian MS Drugs Market Forecast: Revenues ($m), 2015-2026
  • Figure 8.1: Global MS Drugs Market Forecast: Revenues ($m), Annual Growth Rate (%), 2015-2026
  • Figure 8.2: Global MS Drugs Market Broken Down by Therapeutic Segment (Area Graph): Revenues ($m), 2015-2026
  • Figure 8.3: National Markets for MS Drugs (Bar Chart): Revenues ($m), 2015
  • Figure 8.4: National Markets for MS Drugs (Bar Chart): Revenues ($m), 2026

Companies Listed

  • AB Science
  • AbbVie
  • Actelion
  • Active Biotech
  • Apotex
  • Bayer
  • Biogen
  • Canadian Institute for Health Information (CIHI)
  • Celgene
  • Clinicaltrials.gov
  • Committee for Medicinal Products for Human Use (CHMP)
  • Department of Health and Association of the British Pharmaceutical Industry
  • Elan
  • EMA
  • FDA
  • Genentech
  • Genzyme
  • German Institute for Quality and Efficiency in Health Care (IQWiG)
  • GSK
  • Independent Data Safety Monitoring Committee (IDMC)
  • Independent Payment Advisory Board
  • Italian National Health Service
  • Managed Care Magazine
  • MedDay
  • Medicare
  • Medscape
  • Merck KGaA
  • Momenta
  • MS International Federation
  • Multiple Sclerosis Society of Canada
  • Mylan
  • National Institute for Health and Care Excellence (NICE)
  • Neurology
  • NHS
  • Novartis
  • Population Reference Bureau
  • Receptos
  • Reuters
  • Roche
  • Sandoz
  • Sanofi
  • Swiss Re
  • Teva Pharmaceutical Industries
  • The European Commission (EC)
  • The European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • The Lancet Neurology
  • The MS Society
  • The Multiple Sclerosis Foundation
  • Torrent Pharmaceuticals
  • United States National Multiple Sclerosis Society
  • US Patent Trial and Appeal Board
  • Wall Street Journal
  • WHO
Back to Top